Maggie L. Shaw

Treating venous thromboembolism (VTE) in patients can be tricky due to greater risks of major bleeding episodes and recurrent VTE.

The first disease-modifying therapies were introduced in the United States and Canada in the 1990s.

Heart issues in patients with cancer and survivors can present themselves months or years after treatment.

The cost of the expensive treatment varies, based on insurance coverage or lack thereof, and is often out of financial reach of the uninsured.

Disease severity also influences how these patients interact with and react to everyday stimuli.

After a request for additional input from oncologists, practice administrators, payer representatives, and experts in physician payment and business analysis, ASCO has issued updated guidance on PCOP. With CMS’ Oncology Care Model set to end in 2021, the current draft of ASCO’s Community-based Oncology Medical Home model would be an option to take its place.

With their ongoing study, the authors also hope to show the physical effect of exercise on function, quality of life, pain, and bone disease.

Predisposing risk factors include less than a high school education and hepatitis C coinfection.

Quality of life and 6-minute walk test also improve with this treatment combination.

Under the ACA, patients with HIV in Medicaid expansion states have greater access to care.

Tumor inflammatory response is significantly associated with poor prognosis in patients with multiple myeloma.

Researchers aim to eliminate leukemia stem cells safely.

Greater rates of adherence and persistence seen among patients on a single-tablet regimen.

Updated Carthadex trial results show improved responses at the 58-month mark and build on findings from other studies.

For their study, the authors wanted to expand on previous research results that suggest outcomes are improved among patients with multiple myeloma treated at high-volume facilities.

CDC recommends that young men who have sex with men have an HIV test every 6 months.

The rate of decrease in deaths from heart disease (HD) slowed between 2011 and 2014 versus 2000 and 2011, while the population above 65 years jumped 22.9% and there was a concurrent 38% rise in deaths from HD among this patient population.

A recently published commentary examined issues surrounding biosimilars in the treatment of multiple sclerosis from an international point of view, noting the tremendous opportunity for cost savings while wondering if patient concerns are being adequately considered.